Third-generation FLT3 inhibitors in clinical development

CAR T case study in acute myeloid leukemia

Key considerations when prescribing midostaurin with a strong CYP3A4 inhibi

How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance

When to consider iron chelation therapy for a transplant-eligible patient

53-year-old woman presenting with severe fatigue and bruising

New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapy

What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics?

Predictors of response to lenalidomide in a non-del(5q) MDS patient

What are the pros and cons of radiation therapy?

What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma?

Second primary malignancies associated with lenalidomide maintenance

Impact of consolidation therapy in patients post-transplant

Bortezomib as an alternate strategy for maintenance therapy.

What may be the future role for brentuximab vedotin in newly diagnosed Hodgkin lymphoma?

Has MRD testing become a standard of care in multiple myeloma?

The Precision Promise [SM] Initiative: What is it designed to achieve?

Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study

What are the optimal imaging methods to determine extent of bone disease in newly diagnosed MM?

The standard of care for patients receiving lenalidomide or thalidomide who are at high risk for VTE